

Figure S1. Forest plots of studies evaluating hazard ratio of overall survival for PD-L1 expression <1% compared with PD-L1 expression ≥1% in patients treated with chemoradiotherapy followed by consolidation of immune checkpoint inhibitors after excluding studies with sample size <20. PD-L1, programmed cell death-ligand 1; CI, confidence interval.




Figure S2. Forest plots of studies evaluating hazard ratio of progression-free survival for PD-L1 expression <1% compared with PD-L1 expression ≥1% in patients treated with chemoradiotherapy followed by consolidation of immune checkpoint inhibitors after excluding studies with sample size <20. PD-L1, programmed cell death-ligand 1; CI, confidence interval.




Figure S3. Sensitivity analyses. (A) Sensitivity analysis of the meta-analysis results using the leave-one-out method for evaluating hazard ratio of overall survival for PD-L1 expression <1% compared with PD-L1 expression ≥1% in patients treated with consolidation of ICIs after CRT. (B) Sensitivity analysis of the meta-analysis results using the leave-one-out method for evaluating hazard ratio of progression-free survival for PD-L1 expression <1% compared with PD-L1 expression ≥1% in patients treated with consolidation of ICIs after CRT. PD-L1, programmed cell death-ligand 1; ICIs, immune checkpoint inhibitors; CRT, chemoradiotherapy; CI, confidence interval.




Figure S4. Forest plot for pooled OS rates of patients with locally advanced unresectable non-small cell lung cancer and programmed cell death-ligand 1 expression <1% after excluding studies with sample size <20. (A) The pooled 1-year OS rate of the patients treated with CRT alone. (B) The pooled 2-year OS rate of the patients treated with CRT alone. (C) The pooled 3-year OS rate of the patients treated with CRT alone. (D) The pooled 1-year OS rate of the patients treated with CRT followed by consolidation of ICIs. (E) The pooled 2-year OS rate of the patients treated with CRT followed by consolidation of ICIs. (F) The pooled 3-year OS rate of the patients treated with CRT followed by consolidation of ICIs. OS, overall survival; CRT, chemoradiotherapy; ICIs, immune checkpoint inhibitors.




Figure S5. Forest plot for pooled PFS rates of patients with locally advanced unresectable non-small cell lung cancer and programmed cell death-ligand 1 expression <1% after excluding studies with sample size <20. (A) The pooled 1-year PFS rate of the patients treated with CRT alone. (B) The pooled 2-year PFS rate of the patients treated with CRT alone. (C) The pooled 3-year PFS rate of the patients treated with CRT alone. (D) The pooled 1-year PFS rate of the patients treated with CRT followed by consolidation of ICIs. (E) The pooled 2-year PFS rate of the patients treated with CRT followed by consolidation of ICIs. (F) The pooled 3-year PFS rate of the patients treated with CRT followed by consolidation of ICIs. PFS, progression-free survival; CRT, chemoradiotherapy; ICIs, immune checkpoint inhibitors.

